Affimed (NASDAQ:AFMD) Short Interest Update

Affimed (NASDAQ:AFMD) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 718,200 shares, a decline of 9.4% from the August 15th total of 792,600 shares. Based on an average trading volume of 181,600 shares, the days-to-cover ratio is currently 4.0 days. Approximately 5.5% of the company’s shares are sold short.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AFMD. Choreo LLC bought a new stake in Affimed in the second quarter valued at $54,000. Vestal Point Capital LP bought a new stake in Affimed in the 4th quarter valued at about $341,000. Finally, BNP Paribas Financial Markets raised its stake in Affimed by 39.9% during the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after buying an additional 163,162 shares during the period. 30.82% of the stock is owned by institutional investors.

Affimed Price Performance

Affimed stock opened at $3.98 on Tuesday. Affimed has a 52-week low of $2.23 and a 52-week high of $8.95. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.71 and a current ratio of 2.71. The stock’s 50 day moving average price is $4.50 and its two-hundred day moving average price is $5.17.

Wall Street Analyst Weigh In

A number of analysts have weighed in on AFMD shares. Laidlaw increased their target price on shares of Affimed from $15.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. HC Wainwright reiterated a “buy” rating and set a $10.00 price objective on shares of Affimed in a research report on Friday, September 6th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Affimed in a report on Monday, September 9th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. According to MarketBeat, Affimed presently has an average rating of “Moderate Buy” and an average target price of $32.50.

Affimed Company Profile

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.